MediumEndocrinologyType 2 diabetes with cardiorenal riskau-amcau-racp
A 68-year-old man with long-standing type 2 diabetes, obesity and metabolic syndrome has persistently elevated ALT 1.5 times upper limit of normal and ultrasound-confirmed fatty liver. Fibrosis assessment suggests advanced fibrosis. Which class of anti-diabetic agent has additional evidence for benefit in reducing progression of diabetic kidney disease and cardiovascular events and would be preferred if not already used?